2.50
Hdl Handle:
http://hdl.handle.net/10143/64518
Title:
TNFα-hemmere ved inflammatorisk tarmsykdom
Authors:
Ringerike, Tove; Elvsaas, Ida-Kristin Ørjasæter; Coll, Peter; Jahnsen, Jørgen; Lundin, Knut E. A.; Movik, Espen; Gjertsen, Marianne Klemp
Citation:
Rapport fra Kunnskapssenteret 32/2008
Additional Links:
http://www.kunnskapssenteret.no/Publikasjoner/4792.cms

Full metadata record

DC FieldValue Language
dc.contributor.authorRingerike, Tove-
dc.contributor.authorElvsaas, Ida-Kristin Ørjasæter-
dc.contributor.authorColl, Peter-
dc.contributor.authorJahnsen, Jørgen-
dc.contributor.authorLundin, Knut E. A.-
dc.contributor.authorMovik, Espen-
dc.contributor.authorGjertsen, Marianne Klemp-
dc.date.accessioned2009-04-06T11:37:15Z-
dc.date.available2009-04-06T11:37:15Z-
dc.date.issued2008-12-
dc.identifier.citationRapport fra Kunnskapssenteret 32/2008en
dc.identifier.isbn978-82-8121-235-0-
dc.identifier.issn1890-1298-
dc.identifier.urihttp://hdl.handle.net/10143/64518-
dc.description.abstractBACKGROUND Patients with the inflammatory bowel diseases ulcerative colitis and Crohn’s disease need lifelong treatment and care. Effect of traditional treatments is varied and may cause serious adverse events. Biological drugs aimed at blocking specific molecular steps in the inflammatory process have been developed. Tumor necrosis factor (TNF)α is a proinflammatory cytokine with a role in the inflammatory process associated with inflammatory bowel disease. Hence, a drug blocking this cytokine might be useful for patients with ulcerative colitis and Crohn’s disease. This report includes knowledge of the TNFα-inhibitors infliximab (Remicade®), adalimumab (Humira®), etanercept (Enbrel®) and certolizumab pegol (Cimzia®). METHOD We systematically reviewed and critically appraised available documentation on effect and safety of TNFα-inhibitors. In addition, we have reviewed health economic studies. We identified documentation by a systematic search in Cochrane Library, Medline, Embase, PubMed and NHS Economics Evaluation Database. Our evaluation on efficacy and safety was based on systematic reviews. However, to make sure that all available data was included, we searched for randomized controlled trials published afer the literature seach in the systematic reviews was performed. RESULTS In patients with ulcerative colitis, infliximab was more effective than placebo in achieving improvement of the disease. Data on response and remission are available up to 54 weeks. Infliximab gives a higer proportion of patients with endoscopic remission compared to placebo. None of the other TNFα-inhibitors were tested in patients with ulcerative colitis. In patients with Crohn’s disease, infliximab, adalimumab and certolizumab were more effective than placebo in achieving response after induction treatment (1-3 administrations of drug or placebo). Based on patients responding to induction treatment, it has been shown that maintenance treatment with infliximab, adalimumab and certolizumab is more effective than placebo in maintaining the initial response. Infliximab have been showed to be more effective than placebo in achieving fistula closure. Data on etanercerpt in treatment of Crohn’s disease is limited. There is no basis to claim that etanercerpt has effect in treatment of Crohn’s disease. We identified four economic evalutations in a systematic literature search. All studies were from contries outside Norway and delt with infliximabtreatment of patients with Crohn’s disease. CONCLUSION Infliximab is effective in treatment of ulcerative colitis and Crohn’s disease. Adalimumab and certolizumab have documented effect in treatment of Crohn’s disease, while studies on patients with ulcerative colitis are lacking. There is too limited data available to conclude regarding safety of long-term treatment with TNFα-inhibitors for both ulcerative colitis and Crohn’s disease. Based on results from countries outside Norway, infliximab does not seem to be cost-effective as continuous treatment for patients with Crohn’s disease. There might be an exception in the case of patients exhibiting good and long-lasting response. No relevant economic studies were found for ulcerative colitis or for the other TNFα- inhibitors.en
dc.language.isonoen
dc.publisherNorwegian Knowledge Centre for the Health Servicesen
dc.relation.ispartofseriesRapporten
dc.relation.ispartofseries32/2008en
dc.relation.urlhttp://www.kunnskapssenteret.no/Publikasjoner/4792.cmsen
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gasteroenterologi: 773en
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Klinisk farmakologi: 739en
dc.subject.meshCrohn Diseaseen
dc.subject.meshBiological Markersen
dc.subject.meshAntibodiesen
dc.subject.meshAnti-Inflammatory Agentsen
dc.titleTNFα-hemmere ved inflammatorisk tarmsykdomno
dc.title.alternativeTNFα-inhibitors in inflammatory bowel diseaseen
dc.typepeer revieweden
dc.typeReporten
dc.typeReviewen
dc.contributor.departmentNasjonalt kunnskapssenter for helsetjenestenen
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.